Family-owned Swiss cancer specialist Helsinn has reported positive results from a Phase III study of anamorelin in anorexia-cachexia syndrome.
Anamorelin is an investigational once-daily ghrelin receptor agonist and has delivered significant improvements in lean body mass, one of two primary endpoints, in non-small cell lung cancer patients. Anorexia-cachexia affects a majority of advanced cancer patients, and at present existing treatment approaches are limited.
The results underscore the potential for treatment with anamorelin to support the care of patients with CACS, a poorly-understood and debilitating condition that affects a majority of advanced cancer patients but for which existing treatment approaches are limited.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze